10:23 AM EST - StageZero Life Sciences : Announced that for the year ended December 31, 2021, the Company generated $5.1 million in revenue, a 22% increase over the $4.2 million generated in the year prior; gross profit rose to $1.2 million, an increase of $0.5 million over the prior year; comprehensive net loss for the year totaled $7.5 million, or $0.11 loss per fully diluted common share. StageZero Life Sciences
shares T.SZLS are trading unchanged at $0.17.
